Avanos Medical, Inc. (AVNS)
NYSE: AVNS · Real-Time Price · USD
17.87
+0.07 (0.39%)
Nov 20, 2024, 4:00 PM EST - Market closed
Avanos Medical Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | 2018 - 2014 |
|---|---|---|---|---|---|---|---|
Period Ending | Sep '24 Sep 30, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | Dec '19 Dec 31, 2019 | 2018 - 2014 |
| Revenue | 681.5 | 673.3 | 684.1 | 587 | 714.8 | 697.6 | Upgrade
|
| Revenue Growth (YoY) | -0.01% | -1.58% | 16.54% | -17.88% | 2.47% | 6.94% | Upgrade
|
| Cost of Revenue | 303.2 | 293.6 | 289.9 | 287.8 | 343.9 | 295.4 | Upgrade
|
| Gross Profit | 378.3 | 379.7 | 394.2 | 299.2 | 370.9 | 402.2 | Upgrade
|
| Selling, General & Admin | 306.6 | 318.1 | 333.7 | 257.2 | 327.2 | 372.8 | Upgrade
|
| Research & Development | 12.7 | 12.6 | 14.8 | 30.6 | 34.9 | 37.7 | Upgrade
|
| Other Operating Expenses | 2.7 | 3.3 | 3 | 7.3 | 4.4 | -1.4 | Upgrade
|
| Operating Expenses | 322 | 334 | 351.5 | 295.1 | 366.5 | 409.1 | Upgrade
|
| Operating Income | 56.3 | 45.7 | 42.7 | 4.1 | 4.4 | -6.9 | Upgrade
|
| Interest Expense | -12.7 | -15 | -10 | -3.3 | -15.6 | -15 | Upgrade
|
| Interest & Investment Income | 5.3 | 2.9 | 1.2 | 0.2 | 1.2 | 6.7 | Upgrade
|
| EBT Excluding Unusual Items | 48.9 | 33.6 | 33.9 | 1 | -10 | -15.2 | Upgrade
|
| Merger & Restructuring Charges | -21.3 | -31.5 | -7.2 | -28.1 | -25.4 | -26.3 | Upgrade
|
| Legal Settlements | -1.5 | -10 | - | -15 | -27.5 | -22.5 | Upgrade
|
| Pretax Income | 26.1 | -7.9 | 26.7 | -42.1 | -62.9 | -64 | Upgrade
|
| Income Tax Expense | 4.4 | 2 | 5.2 | -11.2 | -33.9 | -18.1 | Upgrade
|
| Earnings From Continuing Operations | 21.7 | -9.9 | 21.5 | -30.9 | -29 | -45.9 | Upgrade
|
| Earnings From Discontinued Operations | -6 | -51.9 | 29 | 37.2 | - | - | Upgrade
|
| Net Income | 15.7 | -61.8 | 50.5 | 6.3 | -29 | -45.9 | Upgrade
|
| Net Income to Common | 15.7 | -61.8 | 50.5 | 6.3 | -29 | -45.9 | Upgrade
|
| Net Income Growth | - | - | 701.59% | - | - | - | Upgrade
|
| Shares Outstanding (Basic) | 46 | 47 | 47 | 48 | 48 | 48 | Upgrade
|
| Shares Outstanding (Diluted) | 46 | 47 | 47 | 49 | 48 | 48 | Upgrade
|
| Shares Change (YoY) | -0.32% | -1.48% | -2.67% | 1.67% | 0.42% | 0.85% | Upgrade
|
| EPS (Basic) | 0.34 | -1.33 | 1.08 | 0.13 | -0.61 | -0.96 | Upgrade
|
| EPS (Diluted) | 0.34 | -1.33 | 1.08 | 0.13 | -0.61 | -0.96 | Upgrade
|
| EPS Growth | - | - | 722.10% | - | - | - | Upgrade
|
| Free Cash Flow | 36.6 | 14.6 | 71.6 | 66.3 | -22.7 | -125.1 | Upgrade
|
| Free Cash Flow Per Share | 0.79 | 0.31 | 1.51 | 1.36 | -0.47 | -2.63 | Upgrade
|
| Gross Margin | 55.51% | 56.39% | 57.62% | 50.97% | 51.89% | 57.65% | Upgrade
|
| Operating Margin | 8.26% | 6.79% | 6.24% | 0.70% | 0.62% | -0.99% | Upgrade
|
| Profit Margin | 2.30% | -9.18% | 7.38% | 1.07% | -4.06% | -6.58% | Upgrade
|
| Free Cash Flow Margin | 5.37% | 2.17% | 10.47% | 11.29% | -3.18% | -17.93% | Upgrade
|
| EBITDA | 104.8 | 91.8 | 90.4 | 42.4 | 47.3 | 30 | Upgrade
|
| EBITDA Margin | 15.38% | 13.63% | 13.21% | 7.22% | 6.62% | 4.30% | Upgrade
|
| D&A For EBITDA | 48.5 | 46.1 | 47.7 | 38.3 | 42.9 | 36.9 | Upgrade
|
| EBIT | 56.3 | 45.7 | 42.7 | 4.1 | 4.4 | -6.9 | Upgrade
|
| EBIT Margin | 8.26% | 6.79% | 6.24% | 0.70% | 0.62% | -0.99% | Upgrade
|
| Effective Tax Rate | 16.86% | - | 19.48% | - | - | - | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.